CClinicalTrials.gg
Not yet recruitingNCT04452851Updated Mar 25, 2025

Portable Positive Pressure Therapy Device

An interventional study of BREATHE and BiPAP in COPD, sponsored by Koronis Biomedical Technologies. Not yet recruiting. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Koronis Biomedical Technologies · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 85 Years
Sex
All
01

Study summary

This study will assess the impact the BREATHE device provides on post-exertion recovery time in COPD patients when used during and/or after performing an Activity of Daily Living simulation. It will also establish equivalency with BiPAP machines.

Read the detailed description

Study Overview: Potential subjects who are clinically stable COPD patients with 30% ≤ FEV1 \< 50% (COPD GOLD criteria stage 3), will be enrolled. Following consent procedures, interested participants will be screened for eligibility. Eligible subjects will be invited to the test facility for four (4) visits. During the first visit, baseline measurements will be made. In the subsequent three (3) sessions, subjects will be asked to perform two (2) tests (BiPAP Equivalency Test and Activity of Daily Living Simulation). Baseline evaluation techniques will include spirometry, a Six Minute Walk Test (6MWT) (which produces a Six Minute Walk Distance, or 6MWD), and finally, a baseline treadmill test. Prior to the baseline treadmill test, Borg Scores will be measured. The subjects will then be asked to walk at a comfortable speed on the treadmill. The incline will be increased each minute by either 1% (Baseline 6MWD \< 250m) or 2% (Baseline 6MWD >250m) until they reached a Borg score of 7.

In subsequent visits, subjects will be randomly assigned each of six tests including: treadmill tests that repeat the baseline treadmill test with a) the prototype BREATHE device, b) a standard BiPAP system, or c) a placebo inhaler used during recovery; and Glittre ADL tests where the subject either has access to the BREATHE device a) withheld, b) during recovery, and c) during test performance and recovery. The primary endpoint in each of these tests is the recovery time (return to 0 Borg, "No difficulty breathing"). SpO2, heart rate, respiration rate, and total test times will also be recorded during each test.

BiPAP Equivalency Test: Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in these tests, after they reach a Borg score of 7, they will be allowed to recover with a) the prototype BREATHE system, b) a standard BiPAP machine, and c) a placebo inhaler until they are fully recovered (Borg: 0).

Activity of Daily Living Simulation: Subjects will be asked to complete Glittre-ADL tests. This test is a standard COPD functional performance instrument. At the beginning of each test, participants will be instructed to rise from a chair and walk 10 meters, ascending a 2-step rise about half-way along that distance, to reach a shelving unit. The shelves will be positioned at shoulder and waist height. The participant will move 3 cartons, each weighing 1 kg, from the upper to the lower shelf and then to the floor.

The sequence is then reversed so that each carton is returned to the top shelf before the participant returns to the starting position at the chair. At that time the participant sits down and then immediately rises to begin the next lap. The test ends when the participant completes 5 of these laps. Participants are told to perform the test as quickly as possible. Rests are allowed but participants are told to resume activity as soon as possible. During the test, participants will wear a backpack filled with a 2.5 (women) or 5 kg (men) weight. The 2.5 kg weight simulates the weight of a supplemental oxygen unit, which can be exchanged for the weight when appropriate. This allows the addition of oxygen for future tests without affecting the integrity of the test.

Three different Glittre-ADL tests will be completed. In these sessions, the BREATHE system will a) not be available, b) be available for use during post-exertion recovery, and c) be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).

02

Conditions studied

  • COPD
03

In context

Lead sponsor

Koronis Biomedical Technologies is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject is age 21 to 85
  • Clinically stable
  • Diagnosis of COPD following ERS-ATS guidelines 2011 update with GOLD criteria stage 3 ("Severe"), 30% ≤ FEV1 \< 50%
  • Capable of giving informed consent
  • Willing and able to comply with the test program as directed by staff.

Exclusion criteria

Exclusion Criteria:

  • Subject is not fluent in written or spoken English
  • Has physical impairment that prevents the subject from being able to walk or stand
  • Is acutely ill/medically complicated, as determined by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treadmill test with BREATHE

    Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with the prototype BREATHE system until they are fully recovered (Borg: 0).

    Device: BREATHE

  • Active comparator
    Treadmill test with BiPAP

    Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a standard BiPAP machine until they are fully recovered (Borg: 0).

    Device: BiPAP

  • Placebo comparator
    Treadmill test with placebo inhaler

    Subjects will perform exercise tests identical to the treadmill tests from the baseline test. However, in this test, after they reach a Borg score of 7, they will be allowed to recover with a placebo inhaler until they are fully recovered (Borg: 0).

    Drug: COPD Inhaler

  • Experimental
    Activity of Daily Living with BREATHE

    Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).

    Device: BREATHE

  • Experimental
    Activity of Daily Living with BREATHE during recovery

    Subjects will be asked to complete Glittre-ADL tests with the BREATHE system being available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).

    Device: BREATHE

  • No intervention
    Activity of Daily Living

    Subjects will be asked to complete Glittre-ADL tests with the BREATHE system will NOT be available for use throughout the test and recovery period. Borg scores will be measured after each minute of exercise and every 30 seconds during seated recovery until the subject is fully recovered (Borg: 0).

Interventions

  • DeviceBREATHE

    The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.

  • DeviceBiPAP

    BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.

  • DrugCOPD Inhaler

    Inhaler medication to support quick relief from COPD symptoms

06

What researchers measure

Primary outcomes

  1. Recovery Time

    The time it takes to return to 0 on the Borg Dyspnoea Scale ("No difficulty breathing") following exercise. This is a scale that asks you to rate the difficulty of your breathing. It starts at number 0 where your breathing is causing you no difficulty at all and progresses through to number 10 where your breathing difficulty is maximal.

    Time frame: 30 minutes

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04452851
Lead sponsor
Koronis Biomedical Technologies
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Mar 25, 2025

Study contacts

Patrick Lichter
Contact
plichter@koronisbiotech.com
6127301091
Robert Knuesel, PhD
Contact
rknuesel@koronisbiotech.com
(507) 459-8625
Robert Knuesel, PhD
principal investigator · Koronis Biomedical Technologies

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion